Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapy
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci174447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Jennifer Gherardini und 15 weiteren Autor:innen. Beteiligte Einrichtung: CUTANEON - Skin & Hair Innovations, Hamburg, Germany. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Hair Follicle, Cyclin-Dependent Kinase Inhibitor p21, Stem Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced alopecia (CIA) remains one of the most distressing adverse effects of cancer therapy. Yet, no therapy is available to selectively protect healthy hair follicles (HFs) and their epithelial stem cells (eHFSCs) from chemotherapy-induced damage without awarding potential survival benefits to cancer cells. Here, we report how human HFs can be protected against 2 lead CIA-inducing chemotherapeutics by inducing selective transient cell cycle arrest. Pretreating scalp HFs before chemotherapy exposure ex vivo with ALRN-6924, a clinical-stage “stapled peptide” drug that binds with high affinity to key endogenous inhibitors of p53, selectively activated p53 signaling only in cells with wild-type TP53 genotype and upregulated p21. This led to temporary cell cycle arrest in healthy tissues without protecting TP53-mutant cancer cells and mitigated chemotherapy-induced HF damage on multiple levels, including excessive hair matrix apoptosis, premature catagen, pigmentary abnormalities, “mitotic catastrophe,” and micronucleation. It also protected eHFSCs against DNA damage, apoptosis, and pathological epithelial-mesenchymal transition. Notably, even topically applied ALRN-6924 afforded relative chemotherapy protection ex vivo. These results provide proof of principle for a strategy to selectively protect rapidly proliferating healthy epithelial tissues and their stem cells in patients with TP53-mutant cancers, which promises to protect against acute and permanent CIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CUTANEON - Skin & Hair Innovations, Hamburg, Germany.
- Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Human Biology, Nicolaus Copernicus University, Toruń, Poland.
- Jose Rodríguez-Feliz, MD, Soléstica Plastic Surgery & MedSpa, Coral Gables, Florida, USA.
- Kassir Plastic Surgery, New York, New York, USA.
- Schönheitsklinik Dr Funk München, Munich, Germany.
Förderung
- NIH
Zitieren
APA
Gherardini, J., Samra, T., Gomez-Gomez, T., Akhundlu, A., Verling, S. D., Linowiecka, K., Wikramanayake, T. C., Knie, U., Rodríguez-Feliz, J., Kassir, R., Funk, W., Azar, R. P., Annis, D. A., Aivado, M., Chéret, J., & Paus, R. (2026). Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci174447
Vancouver
Gherardini J, Samra T, Gomez-Gomez T, Akhundlu A, Verling SD, Linowiecka K, et al. Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapy. Journal of Clinical Investigation. 2026. doi:10.1172/jci174447
BibTeX
@article{Gherardini2026,
author = {Gherardini, Jennifer and Samra, Tara and Gomez-Gomez, Tatiana and Akhundlu, Aysun and Verling, Samantha D and Linowiecka, Kinga and Wikramanayake, Tongyu C and Knie, Ulrich and Rodríguez-Feliz, Jose and Kassir, Ramtin and Funk, Wolfgang and Azar, Reza P and Annis, D Allen and Aivado, Manuel and Chéret, Jérémy and Paus, Ralf},
title = {Transient p53/p21 activation selectively protects healthy human hair follicles and their stem cells from chemotherapy},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci174447}
}
EUVIMED